You are here

Nature DOI:10.1038/s41586-021-03520-4

Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity.

Publication TypeJournal Article
Year of Publication2021
AuthorsGriffin, GK, Wu, J, Iracheta-Vellve, A, Patti, JC, Hsu, J, Davis, T, Dele-Oni, D, Du, PP, Halawi, AG, Ishizuka, JJ, Kim, SY, Klaeger, S, Knudsen, NH, Miller, BC, Nguyen, TH, Olander, KE, Papanastasiou, M, Rachimi, S, Robitschek, EJ, Schneider, EM, Yeary, MD, Zimmer, MD, Jaffe, JD, Carr, SA, Doench, JG, W Haining, N, Yates, KB, Manguso, RT, Bernstein, BE
JournalNature
Date Published2021 May 05
ISSN1476-4687
Abstract

Epigenetic dysregulation is a defining feature of tumorigenesis that is implicated in immune escape. Here, to identify factors that modulate the immune sensitivity of cancer cells, we performed in vivo CRISPR-Cas9 screens targeting 936 chromatin regulators in mouse tumour models treated with immune checkpoint blockade. We identified the H3K9 methyltransferase SETDB1 and other members of the HUSH and KAP1 complexes as mediators of immune escape. We also found that amplification of SETDB1 (1q21.3) in human tumours is associated with immune exclusion and resistance to immune checkpoint blockade. SETDB1 represses broad domains, primarily within the open genome compartment. These domains are enriched for transposable elements (TEs) and immune clusters associated with segmental duplication events, a central mechanism of genome evolution. SETDB1 loss derepresses latent TE-derived regulatory elements, immunostimulatory genes, and TE-encoded retroviral antigens in these regions, and triggers TE-specific cytotoxic T cell responses in vivo. Our study establishes SETDB1 as an epigenetic checkpoint that suppresses tumour-intrinsic immunogenicity, and thus represents a candidate target for immunotherapy.

DOI10.1038/s41586-021-03520-4
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/33953401?dopt=Abstract

Alternate JournalNature
PubMed ID33953401